WHO Says No to Weight-Loss Drugs for Under-10s — and the Debate Is Only Just Starting

The World Health Organization has drawn a firm line in one of the fastest-moving debates in modern medicine. In its first global guidelines on managing obesity in children and adolescents, published on 7 October 2026, the WHO says that children under the age of 10 should not be given weight-loss drugs, bariatric surgery or weight-management devices. Care at that age, it says, belongs with food, movement and family support — not prescriptions.

What the new guidelines say

The headline recommendation is unambiguous. For children under 10, the WHO does not recommend obesity medicines, bariatric surgery or weight-management devices — and it classifies this as a strong recommendation, the highest grade in its system. Luz María De Regil, the agency's director of nutrition and food safety, put it plainly: the foundation of obesity care for children and adolescents is not medicine or surgery, but access to comprehensive support that enables healthy eating, physical activity and sustainable behaviour change.

The guidance is more permissive for older children, but only conditionally. For adolescents aged 10 to 19 with obesity, weight-loss medicines may be considered — but only after supervised, structured lifestyle interventions have been tried and failed, and only when the young person is mentally and physically prepared for treatment. Bariatric surgery enters the picture later still: it may be considered for physically and mentally mature adolescents with severe obesity, and only after at least six months of unsuccessful supervised treatment. For the under-10s, the WHO instead strongly recommends tailored diets, physical activity and behavioural programmes involving caregivers, with supervised digital tools — such as activity trackers and movement-based games — cited as an optional add-on.

It is worth stressing what these guidelines are and are not. They are advisory, not binding: American paediatricians, for instance, generally follow the American Academy of Pediatrics, whose recommendations for teenagers differ in important ways. The WHO itself acknowledges the field is evolving and says it will revise the guidance as trial evidence accumulates.

The scale of the problem behind the caution

The guidelines land against a staggering backdrop. An estimated 170 million children and adolescents worldwide are living with obesity — including some 70 million children aged between five and nine. In that age group, obesity prevalence has quadrupled since 1990, rising from about 2 per cent to 8 per cent. In 2024, a further 35 million children under the age of five were overweight. According to UNICEF data cited around the launch, obesity has now surpassed underweight as the most common form of malnutrition among schoolchildren and adolescents worldwide — a historic reversal with profound implications for health systems everywhere.

Childhood obesity is not a cosmetic concern. It increases the risk of type 2 diabetes and other metabolic conditions, and children who carry excess weight are far more likely to do so as adults. It is precisely because the stakes are so high that the question of how aggressively to treat young children has become so urgent — and so contested.

Why the WHO is saying no to drugs for young children

The core of the WHO's caution is an evidence gap. GLP-1 receptor agonists — the class that includes drugs such as Wegovy — have transformed adult weight management, but the data in young children is vanishingly thin. Only one trial has tested such a drug in children aged six to 11, involving just 82 participants. Trials in teenagers have found larger effects, but they also found something troubling: after one drug was stopped, body mass index rose faster than expected, raising the spectre of lifelong treatment.

That is the question the WHO's experts keep returning to. Laurence Grummer-Strawn, the agency's head of nutrition and food safety actions, framed it as a parent might: if you start children very early on a GLP-1 drug, when does that stop? There is, he said, no real evidence that these drugs can be used as a temporary treatment before handing over to dietary habits later in life. For a child of seven or eight, a prescription could mean a decade or more of injections with unknown long-term effects on growth, development and metabolism. In the WHO's judgement, that is a gamble the current evidence does not support.

There are also practical worries. Weight-management devices and bariatric surgery carry obvious risks for small children, and the WHO's strong recommendation rules them out for the under-10s alongside medicines. The agency is clear that it supports continued clinical research — it wants better evidence, not less science — but argues that caution must come before widespread use.

The GLP-1 boom the guidelines are pushing back against

Context matters here, because the guidelines are a deliberate counterweight to a powerful commercial and cultural tide. GLP-1 medicines have become a global phenomenon among adults, and the pressure is moving down the age ladder. Drug companies are already testing these drugs in children as young as six, the BBC reported, and some doctors are prescribing them outside their licensed age ranges — off-label use driven by desperate families and enthusiastic marketing.

The regulatory picture is genuinely confusing for parents. Novo Nordisk's Wegovy and Saxenda are approved for weight loss in certain adolescents aged 12 and older in the United States and the European Union — and the EU goes further, allowing Saxenda for some children aged 6 to 11. So a parent in Europe can legally obtain for a nine-year-old a drug the WHO now strongly recommends against. That dissonance is exactly why global guidelines matter: they give health ministries, clinicians and families a single evidence-based reference point amid competing commercial messages.

The WHO does not name individual GLP-1 products or issue drug-by-drug rulings; its recommendation is categorical by age group. And De Regil has been careful to say that evidence on GLP-1 drugs in young people remains insufficient while research continues — leaving the door open to revision if future trials deliver the long-term safety data that is currently missing.

What works instead — and the harder question of access

For children under 10, the WHO's prescription is unglamorous but evidence-backed: structured programmes combining healthier diets, regular physical activity and behavioural support, delivered with the active involvement of parents and caregivers. Family-based interventions — where the whole household changes how it eats, moves and spends leisure time — have the strongest track record in the research literature. Digital health tools, from activity trackers to active video games, may help as a supplement under parental supervision, though the evidence there is still limited.

The guidelines also make a point that extends beyond any clinic: healthy diets and physical activity must be accessible and affordable, because treatment alone — whether by drug or by diet plan — cannot halt rising obesity. This is the uncomfortable truth beneath the pharmacology debate. In many countries, the cheapest calories are the least healthy ones, safe spaces for children to play are scarce, and parents working long hours have little bandwidth for structured family programmes. A guideline that recommends lifestyle change without addressing the environment in which lifestyles are lived risks becoming advice that only affluent families can follow.

Why this matters

The WHO's intervention matters for three reasons. First, it gives clinicians a clear, authoritative basis for saying no when parents ask about weight-loss drugs for young children — and demand is rising fast. Second, it reframes childhood obesity as a condition of environments and habits first, and of pharmacology only later and rarely — a stance that pushes health systems towards prevention rather than prescription. Third, it buys time: by holding the line at age 10 while trials continue, the WHO preserves the chance that future guidance will rest on real long-term evidence rather than on extrapolation from adult data.

None of this will be the last word. The trials in young children are already under way, the commercial pressure is immense, and national guidelines will continue to diverge. But for now, the world's leading health authority has spoken with unusual clarity: for children under 10, the answer to obesity is not in an injection pen. It is in the kitchen, the playground, and the daily routines of family life — supported, the WHO insists, by societies willing to make healthy choices the easy ones.